Back to top
more

Amphastar Pharmaceuticals (AMPH)

(Delayed Data from NSDQ)

$21.21 USD

21.21
440,154

+0.26 (1.24%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $21.21 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Centene (CNC) Ties Up to Aid Its Marketplace Members in Chicago

by Zacks Equity Research

Centene's (CNC) product - Ambetter of Illinois - along with RUSH aim to provide improved access to quality healthcare services for CNC's members in Chicago, and thereby grow its Marketplace business.

Sanghamitra Saha headshot

What's in Store for Nasdaq in 2024? 5 Top Picks

by Sanghamitra Saha

After a strong 2023, we expect the Nasdaq to log gains in 2024. Top-ranked Nasdaq stocks GigaCloud Technology Inc (GCT), Carrols Restaurant Group (TAST), Limbach (LMB), Amphastar Pharmaceuticals (AMPH) and Insight Enterprises Inc (NSIT) could emerge as winning picks.

Vaishali Doshi headshot

Snap These 4 Top-Performing Liquid Stocks for Strong Returns

by Vaishali Doshi

Here are four top-ranked liquid stocks, Puma Biotechnology (PBYI), Amphastar Pharmaceuticals (AMPH), DropBox (DBX) and GigaCloud Technology Inc. (GCT), which investors can add to their portfolio for solid gains.

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook Amphastar (AMPH)

by Zacks Equity Research

Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Atossa Genetics Inc. (ATOS) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

Zacks Equity Research

Zacks.com featured highlights Abercrombie & Fitch, Amphastar and NetEase

by Zacks Equity Research

Abercrombie & Fitch, Amphastar and NetEase have been highlighted in this Screen of The Week article.

Zacks Equity Research

Are You Looking for a Top Momentum Pick? Why Amphastar Pharmaceuticals (AMPH) is a Great Choice

by Zacks Equity Research

Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Why You Should Retain UnitedHealth Group (UNH) Stock Now

by Zacks Equity Research

Growing membership, expanding government business, strategic acquisitions, improving operating margin and solid growth outlook poise UnitedHealth Group (UNH) well for growth.

Tirthankar Chakraborty headshot

3 Best Momentum Stocks to Buy Using the Driehaus Strategy

by Tirthankar Chakraborty

Stocks like Abercrombie & Fitch (ANF), Amphastar Pharmaceuticals (AMPH) and NetEase (NTES) have been selected as the momentum picks for the day using the Driehaus strategy.

Zacks Equity Research

Centene (CNC) Wins Contract From Arizona's Medicaid Agency

by Zacks Equity Research

Centene's (CNC) Arizona subsidiary has been chosen by the AHCCCS to improve health outcomes for the state's ALTCS-E/PD members and further solidify statewide presence.

Vaishali Doshi headshot

4 Top-Performing Liquid Stock Picks for Robust Returns

by Vaishali Doshi

Here are four top-ranked liquid stocks, Puma Biotechnology (PBYI), Amphastar Pharmaceuticals (AMPH), DropBox (DBX), and Vimeo (VMEO), which investors can add to their portfolio for solid gains.

Zacks Equity Research

Amphastar (AMPH) Is Considered a Good Investment by Brokers: Is That True?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Amphastar (AMPH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks Equity Research

Here's Why Investors Should Retain Molina Healthcare (MOH) Now

by Zacks Equity Research

Molina Healthcare (MOH) is well-poised for improvement on the back of membership growth in the Medicaid and Medicare businesses. Acquisitions and a solid cash balance act as added tailwinds.

Zacks Equity Research

Here's Why You Should Invest in Centene (CNC) Stock Now

by Zacks Equity Research

Robust growth outlook, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook Amphastar (AMPH)

by Zacks Equity Research

Amphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?

by Zacks Equity Research

Here is how Cencora (COR) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

Zacks Equity Research

Wall Street Analysts See Amphastar (AMPH) as a Buy: Should You Invest?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Amphastar (AMPH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Rises Yet Lags Behind Market: Some Facts Worth Knowing

by Zacks Equity Research

In the most recent trading session, Amphastar Pharmaceuticals (AMPH) closed at $45.27, indicating a +0.2% shift from the previous trading day.

Zacks Equity Research

Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies

by Zacks Equity Research

Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies are part of the Zacks Industry Outlook article.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why

by Zacks Equity Research

The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $45.19, representing a +1.23% change from its previous close.

Sundeep Ganoria headshot

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

by Sundeep Ganoria

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, AMPH and SLGL.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Rises As Market Takes a Dip: Key Facts

by Zacks Equity Research

In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $44.72, denoting a +0.52% change from the preceding trading day.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why

by Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) closed at $46.47 in the latest trading session, marking a +1.55% move from the prior day.

Zacks Equity Research

Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?

by Zacks Equity Research

Here is how Amphastar Pharmaceuticals (AMPH) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Rises Higher Than Market: Key Facts

by Zacks Equity Research

In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $47.55, denoting a +0.76% change from the preceding trading day.